PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...
Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results